Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Molecular Diagnostics » Oncocyte Provides Post-Mortem on DetermaDx Failure, Describes Renewed Focus on Remaining Assays

Oncocyte Provides Post-Mortem on DetermaDx Failure, Describes Renewed Focus on Remaining Assays

Jul 30, 2020
|
Molika Ashford
Premium

NEW YORK – Diagnostic firm Oncocyte made a surprising announcement this June that it was discontinuing efforts to bring its blood-based lung cancer detection assay, DetermaDx, to the clinic, after more than five years of development and having reached the final stages of clinical validation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

From the Recovered

According to the Wall Street Journal, the Food and Drug Administration may soon issue an Emergency Use Authorization for convalescent plasma to treat COVID-19 patients.

Minnesota Cold Case Arrest

Minnesota police have used genetic genealogy to make an arrest in a 1986 cold case, reports NBC News.

Editing Squid

Researchers have used CRISPR-Cas9 to efficiently target a cephalopod pigmentation gene, as they report in Current Biology.

Science Papers Examine Human Fetal Microglia Development, Structure of Adenine Base Editor ABE8e

In Science this week: chromatin accessibility of microglia during fetal development, and more.

Aug
18
Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Sponsored by
Bio-Rad

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Aug
27
Featured Webinar

CRISPR/Cas9 Screens to Investigate Mechanisms of Cancer Drug Resistance

Sponsored by
Cellecta

Over 70 percent of breast cancers are estrogen receptor positive and are treated with endocrine therapy.

What's Popular?

In Infectious Disease

  1. NIH Awards $249M to Seven Firms for Rapid Acceleration of COVID-19 Diagnostics

  2. Saliva Samples Slow to Catch On for Large-Scale Coronavirus Testing

    Premium

  3. Clinical Reference Laboratory Gets FDA Emergency Use Authorization for COVID-19 Saliva PCR Test

  4. SARS-CoV-2 E Gene SNP Raises Concerns About Test Accuracy, Transparency

    Premium

  5. Frequent COVID-19 Testing May Enable Campus Reopenings But Logistics Are Challenging, Model Says

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.